

Figure 1




Figure 2






Figure 3

**Figure 4**

**Figure 5**




Figure 6

Fibrinogen Family Tree




FIGURE 8



PURIFICATION SCHEME

FIGURE 9


Western Blot (under non-reducing conditions)



Lane	Sample
1.	hfib, 100 ngs
2.	TG 1-11-4 (pellet-2), 15 ngs
3.	TG 1-11-4 (pellet-2), 15 ngs
4.	TG 1-6-9 (pellet-2), 30 ngs
5.	TG 1-6-9 (pellet-2), 30 ngs
6.	Diafiltered mouse plasma, 1-2 μ gs
7.	NTG (pellet-2), 600 ngs
8.	hfib, 10 ngs

FIGURE 10


Western Blot (SDS-PAGE under Reducing Conditions)



Lane	Sample
1.	human Fibrinogen (100 ngs)
2.	hFib (50 ngs)
3.	hFib (10 ngs)
4.	Mouse Plasma Derivative (200 ngs)
5.	TG whey (pellet-2) 60 ngs
6.	TG whey (pellet-2) 30 ngs
7.	TG whey (pellet-2) 15 ngs
8.	TG whey (pellet-2) 8 ngs

FIGURE 11


Analysis of products under reducing conditions
Thrombin assisted clot formation



Lane	Sample
1.	hFib (50 ngs)-before Thrombin
2.	hFib (10 ngs)-before Thrombin
3.	hFib (10 ngs)-resuspended clot
4.	TG whey (pellet-2) 30 ngs-before Thrombin
5.	TG whey (pellet-2)-resuspended clot
6.	Mouse Plasma Derivative 1000 ngs-before Thrombin
7.	Mouse Plasma Derivative 1000 ngs-resuspended

FIGURE 12

FPA EIA (on Immobilon AV)



ID#	Sample
Lanes 1-6	FPA standard**. (200-6.25 ngs)
Lane 7	TG whey-Before thrombin
Lane 8	TG whey (clot supernatant)-After Thrombin
Lane 9	NTG whey-before thrombin
Lane 10	NTG whey (clot supernatnat)-After Thrombin.
Lane 11	hfib (1 mg/ml)-after Thrombin
Lane 12	hfib (1 mg/ml)-before Thrombin
Lane 13	Mouse Plasma-after Thrombin
Lane 14	Mouse Plasma-before Thrombin

** FPA was serially diluted in clot supernatant from NTG whey.